linagliptin low dose
1218.62
Phase 2 small_molecule completed
Quick answer
linagliptin low dose for Diabetes Mellitus, Type 2 is a Phase 2 program (small_molecule) at Boehringer Ingelheim with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim
- Indication
- Diabetes Mellitus, Type 2
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed